Symbolbild · KI-generiert
Medexus Pharmaceuticals Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Medexus is a leading pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on hematology and hemato-oncology products, including cell and gene therapy products, and historically also on rheumatology and allergy products.
Company description as published by the issuer via TMX Money.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Medexus Pharmaceuticals Inc. | MDP | TSX | 115 Mio. USD |
| Exagen Inc. | XGN | NASDAQ | 109 Mio. USD |
| DIRTT Environmental Solutions Ltd. | DRT | TSX | 120 Mio. USD |
| BioSyent Inc. | RX | TSXV | 121 Mio. USD |
| Custom Health Holdings Inc. | CHLT | TSX | 122 Mio. USD |
| Cannara Biotech Inc. | LOVE | TSX | 131 Mio. USD |
| Organigram Global Inc. | OGI | TSX | 132 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.